{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:16:06Z","timestamp":1791141366787,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Chronic lymphocytic leukemia (CLL) is characterized by high individual variability in clinical course and the need for therapy. Differentiation of prognostic subgroups is based primarily on the mutation status of the genes for the variable region of the immunoglobulin heavy chain (IGHV). The time- and labor-intensive nature of this analysis necessitates the use of easily applicable surrogate markers.<\/jats:p>\n               <jats:p>Methods: We developed a quantitative PCR (qPCR) method for determining lipoprotein lipase (LPL) mRNA expression and analyzed samples of lysed whole blood and CD19-selected cells from 50 CLL patients. Associations of LPL and ZAP70 [\u03b6-chain (TCR) associated protein kinase 70 kDa] expression with IGHV mutation status, overall survival (OS), and treatment-free survival (TFS) were investigated.<\/jats:p>\n               <jats:p>Results: Lysed samples of whole blood and CD19-selected cells were similar with respect to LPL expression (R = 0.88; P &amp;lt;0.0001). LPL expression was significantly associated with IGHV mutation status [\u03c72(1) = 15.3; P &amp;lt;0.0001] and showed an 89.3% specificity, a 68.2% sensitivity, an 83.3% positive predictive value, and a 78.1% negative predictive value for IGHV mutation status. LPL expression was significantly associated with both OS and TFS in log-rank tests (both P values = 0.002). LPL-positive patients had a significantly shorter median TFS time (23 months) than LPL-negative patients (88 months) (P = 0.002).<\/jats:p>\n               <jats:p>Conclusions: LPL mRNA expression is a valuable prognostic marker in CLL. The method does not require cell purification, and its applicability with archived samples facilitates its use in the clinical routine and other studies.<\/jats:p>","DOI":"10.1373\/clinchem.2006.076331","type":"journal-article","created":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T20:34:32Z","timestamp":1165523672000},"page":"204-212","source":"Crossref","is-referenced-by-count":43,"title":["Lipoprotein Lipase mRNA Expression in Whole Blood Is a Prognostic Marker in B Cell Chronic Lymphocytic Leukemia"],"prefix":"10.1093","volume":"53","author":[{"given":"Femke","family":"Van Bockstaele","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Pede","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Callewaert","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verhasselt","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Philippe\u0301","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"2020022802413377500_R1","doi-asserted-by":"crossref","unstructured":"Hamblin AD, Hamblin TJ. Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia. Expert Opin Ther Targets2005;9:1165-1178.","DOI":"10.1517\/14728222.9.6.1165"},{"key":"2020022802413377500_R2","unstructured":"Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica2005;90:391-399."},{"key":"2020022802413377500_R3","doi-asserted-by":"crossref","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood1975;46:219-234.","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"2020022802413377500_R4","doi-asserted-by":"crossref","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198-206.","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"2020022802413377500_R5","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:1840-1847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2020022802413377500_R6","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:1848-1854.","DOI":"10.1182\/blood.V94.6.1848"},{"key":"2020022802413377500_R7","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med2001;194:1639-1647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020022802413377500_R8","doi-asserted-by":"crossref","unstructured":"Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood2003;101:4944-4951.","DOI":"10.1182\/blood-2002-10-3306"},{"key":"2020022802413377500_R9","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:1764-1775.","DOI":"10.1056\/NEJMoa023143"},{"key":"2020022802413377500_R10","doi-asserted-by":"crossref","unstructured":"Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia2003;17:2426-2434.","DOI":"10.1038\/sj.leu.2403147"},{"key":"2020022802413377500_R11","doi-asserted-by":"crossref","unstructured":"Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet2004;363:105-111.","DOI":"10.1016\/S0140-6736(03)15260-9"},{"key":"2020022802413377500_R12","doi-asserted-by":"crossref","unstructured":"Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893-901.","DOI":"10.1056\/NEJMoa040857"},{"key":"2020022802413377500_R13","doi-asserted-by":"crossref","unstructured":"Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B cell chronic lymphocytic leukemia. Leukemia2005;19:750-758.","DOI":"10.1038\/sj.leu.2403707"},{"key":"2020022802413377500_R14","doi-asserted-by":"crossref","unstructured":"Del Giudice I, Morilla A, Osuji N, Matutes E, Morilla R, Burford A, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer2005;104:2124-2132.","DOI":"10.1002\/cncr.21437"},{"key":"2020022802413377500_R15","unstructured":"Laurenti L, Petlickovski A, Rumi C, Gobessi S, Piccioni P, Tarnani M, et al. Comparison of ZAP-70\/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica2005;90:1533-1540."},{"key":"2020022802413377500_R16","doi-asserted-by":"crossref","unstructured":"Vener C, Gianelli U, Cortelezzi A, Fracchiolla NS, Somalvico F, Savi F, et al. ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. Leuk Lymphoma2006;47:245-251.","DOI":"10.1080\/10428190500272846"},{"key":"2020022802413377500_R17","doi-asserted-by":"crossref","unstructured":"Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, et al. The LPL\/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood2005;106:650-657.","DOI":"10.1182\/blood-2004-08-3344"},{"key":"2020022802413377500_R18","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med2001;194:1625-1638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020022802413377500_R19","unstructured":"van\u2019t Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica2006;91:56-63."},{"key":"2020022802413377500_R20","doi-asserted-by":"crossref","unstructured":"Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, et al. High expression of lipoprotein lipase in poor risk B cell chronic lymphocytic leukemia. Leukemia2005;19:1216-1223.","DOI":"10.1038\/sj.leu.2403748"},{"key":"2020022802413377500_R21","doi-asserted-by":"crossref","unstructured":"Moreau EJ, Matutes E, A\u2019Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol1997;108:378-382.","DOI":"10.1093\/ajcp\/108.4.378"},{"key":"2020022802413377500_R22","doi-asserted-by":"crossref","unstructured":"Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol1992;29:193-203.","DOI":"10.1016\/0161-5890(92)90100-C"},{"key":"2020022802413377500_R23","unstructured":"Aubin J, Davi F, Nguyen-Salomon F, Leboeuf D, Debert C, Taher M, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia1995;9:471-479."},{"key":"2020022802413377500_R24","doi-asserted-by":"crossref","unstructured":"Claeys S, De Belder T, Holtappels G, Gevaert P, Verhasselt B, Van Cauwenberge P, Bachert C. Macrophage mannose receptor in chronic sinus disease. Allergy2004;59:606-612.","DOI":"10.1111\/j.1398-9995.2004.00471.x"},{"key":"2020022802413377500_R25","doi-asserted-by":"crossref","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe Against Cancer program. Leukemia2003;17:2474-2486.","DOI":"10.1038\/sj.leu.2403136"},{"key":"2020022802413377500_R26","doi-asserted-by":"crossref","unstructured":"Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood2006;107:2090-2093.","DOI":"10.1182\/blood-2005-04-1483"},{"key":"2020022802413377500_R27","doi-asserted-by":"crossref","unstructured":"Philippe\u0301 J, Van Bockstaele F, Smits K, Offner F, Verhasselt B, Janssens A. The restricted VH-gene usage is of prognostic value in B-Cell chronic lymphocytic leukemia. ASH Annual Meeting Abstracts2004;104:528-529.","DOI":"10.1182\/blood.V104.11.1911.1911"},{"key":"2020022802413377500_R28","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia2002;16:993-1007.","DOI":"10.1038\/sj.leu.2402537"},{"key":"2020022802413377500_R29","doi-asserted-by":"crossref","unstructured":"Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, et al. Analysis of clonal B cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol2001;115:854-861.","DOI":"10.1046\/j.1365-2141.2001.03149.x"},{"key":"2020022802413377500_R30","doi-asserted-by":"crossref","unstructured":"Van Bockstaele F, Janssens A, Piette A, Callewaert F, Pede V, Offner F, et al. Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgVH mutation status. Cytometry B Clin Cytom2006;70B:302-308.","DOI":"10.1002\/cyto.b.20122"},{"key":"2020022802413377500_R31","doi-asserted-by":"crossref","unstructured":"Thach DC, Lin B, Walter E, Kruzelock R, Rowley RK, Tibbetts C, et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. J Immunol Methods2003;283:269-279.","DOI":"10.1016\/j.jim.2003.10.004"},{"key":"2020022802413377500_R32","doi-asserted-by":"crossref","unstructured":"Kolset SO, Salmivirta M. Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cell Mol Life Sci1999;56:857-870.","DOI":"10.1007\/s000180050031"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/2\/204\/32689433\/clinchem0204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/2\/204\/32689433\/clinchem0204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T02:43:12Z","timestamp":1582857792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/53\/2\/204\/5627429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,2,1]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.076331","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,2,1]]},"published":{"date-parts":[[2007,2,1]]}}}